Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
- 21 September 2021
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 33 (1), 20-33
- https://doi.org/10.1016/j.annonc.2021.09.005
Abstract
No abstract availableFunding Information
- European Society for Medical Oncology
This publication has 71 references indexed in Scilit:
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsThe Lancet Oncology, 2012
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trialThe Lancet Oncology, 2010
- SDHB immunohistochemistry: a useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumorsLaboratory Investigation, 2010
- Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 CasesThe American Journal of Surgical Pathology, 2010
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Journal of Surgical Oncology, 2008
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KITJournal of Clinical Oncology, 2008
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004